Section 118E:80 - [Multiple versions] Review of available covered medications, treatments, and adequacy of services; report(a) Every 2 years, not later than November 15, the executive office shall review data and report on findings from the review based on data collected for the prior 2 years. The review shall consist of: (i) the available covered medications; (iii) whether health care services were adequate to meet the needs of enrollees, including, but not limited to, input received pursuant to subsection (c). Each report shall include, but not be limited to: (A) detailed results of the review; (B) recommendations, if any, for improvements in the delivery of health care services to enrollees with a diagnosis of sickle cell disease; and (C) recommendations, if any, on whether the division shall seek to add or facilitate access to additional medications, treatments or services.(b) Each review pursuant to subsection (a) shall include, but not be limited to: (i) the extent to which healthcare transitional programs or services for enrollees that are covered by the division prepare, transfer and integrate emerging adults with sickle cell disease into the adult care setting;(ii) the extent to which providers of emergency medical services to enrollees are adequately trained and otherwise prepared to treat and manage sickle cell patients presenting with vaso-occlusive crises, including, but not limited to, the extent to which such providers follow clinically-validated algorithms and protocols regarding such treatment and management; and(iii) the number of people with sickle cell disease who had 2 or more hospitalizations or emergency department visits with a vaso-occlusive episode or pain crisis, including the average length of stay for such visits.(c) When conducting a review pursuant to subsection (a), the executive office shall solicit and consider input from the public, with specific emphasis on receiving input from patients with a sickle cell disease diagnosis as well as persons or groups with knowledge, experience or specialized expertise in the area of sickle cell disease treatment. Not later than April 30 of each year that the review is conducted, the executive office shall hold not less than 1 public hearing to solicit input.(d) Each report required under this section shall be filed with the clerks of the house of representatives and the senate, the joint committee on health care financing and the house and senate committees on ways and means. The division shall post the report on the division's website in a manner accessible by the public.Mass. Gen. Laws ch. 118E, § 80
Added by Acts 2022, c. 126,§ 67, eff. 7/1/2022.